BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18196272)

  • 1. Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques.
    Yue Y; Wang Z; Abel K; Li J; Strelow L; Mandarino A; Eberhardt MK; Schmidt KA; Diamond DJ; Barry PA
    Med Microbiol Immunol; 2008 Jun; 197(2):117-23. PubMed ID: 18196272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.
    Abel K; Martinez J; Yue Y; Lacey SF; Wang Z; Strelow L; Dasgupta A; Li Z; Schmidt KA; Oxford KL; Assaf B; Longmate JA; Diamond DJ; Barry PA
    J Virol; 2011 Mar; 85(6):2878-90. PubMed ID: 21191005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.
    Wussow F; Yue Y; Martinez J; Deere JD; Longmate J; Herrmann A; Barry PA; Diamond DJ
    J Virol; 2013 Feb; 87(3):1322-32. PubMed ID: 23152525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.
    Abel K; Strelow L; Yue Y; Eberhardt MK; Schmidt KA; Barry PA
    Vaccine; 2008 Nov; 26(47):6013-25. PubMed ID: 18760319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
    Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
    Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques.
    Yue Y; Kaur A; Eberhardt MK; Kassis N; Zhou SS; Tarantal AF; Barry PA
    J Virol; 2007 Feb; 81(3):1095-109. PubMed ID: 17108040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
    Horton H; Vogel TU; Carter DK; Vielhuber K; Fuller DH; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Montefiori DC; Erfle V; Desrosiers RC; Wilson N; Picker LJ; Wolinsky SM; Wang C; Allison DB; Watkins DI
    J Virol; 2002 Jul; 76(14):7187-202. PubMed ID: 12072518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
    Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
    J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex.
    Wussow F; Chiuppesi F; Martinez J; Campo J; Johnson E; Flechsig C; Newell M; Tran E; Ortiz J; La Rosa C; Herrmann A; Longmate J; Chakraborty R; Barry PA; Diamond DJ
    PLoS Pathog; 2014 Nov; 10(11):e1004524. PubMed ID: 25412505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
    Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
    PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
    Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
    J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.
    Manuel ER; Wang Z; Li Z; La Rosa C; Zhou W; Diamond DJ
    Virology; 2010 Aug; 403(2):155-62. PubMed ID: 20471051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.
    Gil A; Shen S; Coley S; Gibson L; Diamond DJ; Wang S; Lu S
    Hum Vaccin Immunother; 2013 Oct; 9(10):2120-32. PubMed ID: 24051429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques.
    Styles TM; Gangadhara S; Reddy PBJ; Sahoo A; Shiferaw A; Welbourn S; Kozlowski PA; Derdeyn CA; Velu V; Amara RR
    Front Immunol; 2022; 13():914969. PubMed ID: 35935987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.
    Wang Z; La Rosa C; Li Z; Ly H; Krishnan A; Martinez J; Britt WJ; Diamond DJ
    Vaccine; 2007 Jan; 25(6):1132-41. PubMed ID: 17049414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65).
    Yue Y; Kaur A; Zhou SS; Barry PA
    J Gen Virol; 2006 Apr; 87(Pt 4):777-787. PubMed ID: 16528025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
    Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
    J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.